Olaparib is a breast cancer treatment that could save lives. However, in November 2022, it was provisionally rejected for use on the NHS in England.

In response, we launched a campaign, calling on pharmaceutical company, AstraZeneca, NICE and NHS England to find a solution to make olaparib available to the women who could benefit from it.


Over 70,000 sign our petition

Our Chief Executive has now written to AstraZeneca, NICE and NHS England on behalf of the more than 70,000 people who backed the campaign and signed our petition.


Thank you

We want to say a massive thank you to everybody who added their name and helped us send the strongest message possible that this drug needs to be made available on the NHS.

We hope to hear a final decision soon and we will update you as soon as we do.

To find out about the outcome of the campaign and keep up to date with our other work, please sign up for campaign updates below.

“It’s daunting to know that your breast cancer is less common and more aggressive than other types of breast cancer, with a higher risk of returning in the years immediately following treatment. I feel incredibly lucky to have been given the opportunity to benefit from olaparib. Given the significant reduction in the risk of breast cancer recurring that it provides It’s vital that other eligible women with primary breast cancer are able to benefit from olaparib too.”

A patient with BRCA positive, primary triple negative breast cancer, who has been receiving olaparib via the drug company’s early access programme.

Frequently asked questions